title: The effects of neutrophils and phospholipase A2 on transvascular albumin flux in isolated rabbit lungs.
abstract: In this study, addition of phospholipase A2 (PLA2) to salt-perfused isolated rabbit lungs containing rabbit polymorphonuclear leukocytes leads to an increase in pulmonary capillary permeability. We add 1.5 X 10(8) polymorphonuclear leukocytes to the perfusate. Next, indomethacin is added to the perfusate and 40 units of PLA2 are infused into the pulmonary arterial inflow of the lungs. At the end of the study, a lung sample is removed for measurement of transvascular albumin flux using I125-albumin as a measure of the permeability-surface area product. Control studies demonstrate no increase in transvascular albumin flux. Addition of a dual cyclooxygenase and lipoxygenase inhibitor, BW755C, to the perfusate prevents the increase in transvascular albumin flux. We conclude that PLA2 interacts with polymorphonuclear leukocytes to increase protein permeability. Since PLA2 can release endogenous arachidonic acid and platelet-activating factor from cells, this suggests that release of such products may contribute to an increase in pulmonary capillary permeability from polymorphonuclear leukocytes. The ability of BW755C to prevent the increase suggests the possibility that lipoxygenase products contribute.
authors.affiliation: Department of Medicine, Veterans Administration Medical Center, Sepulveda, California 91343.
authors.forename: M R
authors.initials: MR
authors.lastname: Littner
authors.forename: F D
authors.initials: FD
authors.lastname: Lott
mesh_terms: D015772:4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine / Q000494:pharmacology; D000818:Animals; D001794:Blood Pressure; D002199:Capillary Permeability; D016861:Cyclooxygenase Inhibitors; D006325:Heart Atria / Q000187:drug effects; D016859:Lipoxygenase Inhibitors; D008168:Lung / Q000502:physiology*; D009504:Neutrophils / Q000502:physiology*; D010740:Phospholipases / Q000494:pharmacology*; D010741:Phospholipases A / Q000494:pharmacology*; D054467:Phospholipases A2; D011651:Pulmonary Artery / Q000187:drug effects; D011817:Rabbits; D012709:Serum Albumin / Q000378:metabolism*
chemical_list: D016861:Cyclooxygenase Inhibitors; D016859:Lipoxygenase Inhibitors; D012709:Serum Albumin; D015772:4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine; D010740:Phospholipases; D010741:Phospholipases A; D054467:Phospholipases A2